Health & bio

AbbVie ELAHERE Plus Carboplatin: 62.7% Phase 2 ORR

At SGO 2026 (April 10–13, San Juan), AbbVie presented Phase 2 data (IMGN853-0420) showing mirvetuximab plus carboplatin achieved a 62.7% objective response rate in platinum-sensitive ovarian cancer.

Primary sources · 1
AbbVie news
← View the full 2026-04-11 (Sat) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →